Breast Elasticity Imaging During Neoadjuvant Chemotherapy

Summary

For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.

Eligibility

Inclusion Criteria:

* Women age ≥18
* Deemed eligible to receive neoadjuvant systemic therapy as per the treating physician, with the dose and schedule deemed appropriate by the treating physician.
* Any stage invasive breast cancer provided the primary breast tumor size is ≥ 4 mm

Exclusion criteria:

* Patient is pregnant or lactating
* Presence of breast implants
* History of laser or radiation therapy to the affected breast

Conditions2

Locations1 site

Browse More Trials